Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The firms launched the global Phase II bladder cancer trial for autogene cevumeran after seeing early success in pancreatic ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

Bharat Biotech also launched a nasal COVID-19 vaccine— iNCOVACC ... Novavax- Nuvaxovid, Pfizer BioNTech Comirnaty, Pfizer BioNTech Comirnaty (bivalent), SII Covishield, SII Covavax, Sinopharm Beijing ...

The Trump administration plans to impose a new testing requirement for new vaccines — a demand that could delay the availability of the next round of COVID-19 vaccines and complicate the ...

Pieter Cullis a co-founder and have shares in Acuitas Therapeutics, the company that provided the LNP enabling the Pfizer/BioNTech COVID-19 vaccine. He receives funding from CIHR. University of ...

Such a move would be costly and suggests a potential shift in how the agency may approach coronavirus vaccines going forward. Typically, Pfizer and Moderna get instructions from the FDA on how to ...